| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
William K. McVicar is Director at DCOY. The disclosed holdings are worth an estimated $3K at current prices.
Net of sales, the DCOY filings show accumulation of 35,253 shares.
William K. McVicar has 16 Form 4 filings on record from June 2015 to August 2026, across 2 companies: Director at Decoy Therapeutics (DCOY), 2017–2026; Rocket Pharmaceuticals (RCKT), 2015–2016.
The 16 reported transactions were 11 option or other derivative awards, 3 open-market purchases and 2 stock awards.
Counted by filing, the open-market trades come to 2 purchases worth about $15K and no sales.
The largest open-market purchase was 8,700 shares of DCOY at an average $1.15 on February 11, 2020, about $10K.